rdf:type |
|
lifeskim:mentions |
umls-concept:C0017262,
umls-concept:C0185117,
umls-concept:C0205314,
umls-concept:C0242643,
umls-concept:C0441655,
umls-concept:C0596402,
umls-concept:C0679622,
umls-concept:C1515655,
umls-concept:C1519143,
umls-concept:C1533691,
umls-concept:C2911684
|
pubmed:issue |
12
|
pubmed:dateCreated |
2005-8-15
|
pubmed:abstractText |
SJG-136 is a novel pyrrolobenzodiazepine dimer analogue that acts as a minor-groove interstrand DNA cross-linking agent. The present study investigated the impact of ABCB1 (mdr-1) expression on the activity of SJG-136 using both in vitro and in vivo systems. SJG-136 was highly potent in the colon cancer cell lines HCT-116, HT-29 and SW620 (IC50 0.1-0.3 nM). However, HCT-8 and HCT-15 cells expressing significant levels of mdr-1 were less sensitive (IC50 2.3 and 3.7 nM, respectively) using a SRB assay. The cytotoxicity was increased in HCT-15 and A2780(AD) in presence of 5 microg/ml verapamil. Mdr-1 mRNA expression was determined by qRT-PCR and correlated to SJG-136 IC50s (r2=0.86, P=0.0001). Isogenic 3T3 cells expressing mdr-1 cDNA (3T3 pHamdr-1) were less sensitive to SJG-136 than the parental 3T3 cells (IC50 208 and 6.3 nM, respectively). Finally, SJG-136 (120 microg/kg/d dx5) was highly active against A2780 xenografts (SGD=275) but not A2780(AD) xenografts (SGD=67).
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/1,1'-((propane-1,3-diyl)dioxy)bis(7-...,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Benzodiazepinones,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations,
http://linkedlifedata.com/resource/pubmed/chemical/P-Glycoprotein,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrroles,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Verapamil
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0959-8049
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
41
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1811-8
|
pubmed:meshHeading |
pubmed-meshheading:16046116-Animals,
pubmed-meshheading:16046116-Antineoplastic Agents,
pubmed-meshheading:16046116-Benzodiazepinones,
pubmed-meshheading:16046116-Cell Line, Tumor,
pubmed-meshheading:16046116-Colonic Neoplasms,
pubmed-meshheading:16046116-Drug Combinations,
pubmed-meshheading:16046116-Humans,
pubmed-meshheading:16046116-Immunoblotting,
pubmed-meshheading:16046116-Inhibitory Concentration 50,
pubmed-meshheading:16046116-Mice,
pubmed-meshheading:16046116-Mice, Inbred C57BL,
pubmed-meshheading:16046116-P-Glycoprotein,
pubmed-meshheading:16046116-Pyrroles,
pubmed-meshheading:16046116-RNA, Messenger,
pubmed-meshheading:16046116-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:16046116-Transplantation, Heterologous,
pubmed-meshheading:16046116-Verapamil
|
pubmed:year |
2005
|
pubmed:articleTitle |
Influence of P-glycoprotein expression on in vitro cytotoxicity and in vivo antitumour activity of the novel pyrrolobenzodiazepine dimer SJG-136.
|
pubmed:affiliation |
Pharmacology and Drug Development Team, Cancer Research UK Centre, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh EH4 2XR, UK. Sylvie.guichard@cancer.org.uk
|
pubmed:publicationType |
Journal Article
|